DLA Piper advises Pfizer on $600 million vaccine acquisition
DLA Piper has advised Pfizer on the acquisition of the commercial division of vaccines from Baxter. The deal, with a global volume of over US $600 million, has created a new division of Pfizer in the Austrian market.
Pfizer acquired a portfolio of two vaccines and the corresponding Austrian production facilities in Orth an der Donau. The two vaccines can protect against certain forms of meningitis, partially transmitted through tick bites. Following the completion of the transaction Pfizer will have its own production site in Austria.